Immunohistochemical characteristics of epithelial-mesenchymal transition in pancreatic ductal adenocarcinoma

Authors

DOI:

https://doi.org/10.14739/2310-1210.2024.2.297243

Keywords:

pancreatic ductal adenocarcinoma, pancreas, epithelial to mesenchymal transition (EMT), immunohistochemistry, E-cadherin, beta-catenin, alpha-SMA, vimentin, cytokeratin 7 (CK7), cytokeratin 18 (CK18)

Abstract

The epithelial-mesenchymal transition (EMT) plays a crucial role in the development of pancreatic ductal adenocarcinoma (PDAC). There are insufficient and contradictory data in the scientific literature on the peculiarities of epithelial and mesenchymal marker expression in PDAC ducts and EMT zone, which requires further research on the role of EMT in the development and progression of PDAC.

Aim: to conduct a comprehensive assessment of epithelial and mesenchymal markers of EMT in the PDAC ducts and EMT zone at different degrees of differentiation.

Materials and methods. A comprehensive pathomorphological and immunohistochemical examination including 49 cases of surgical material from patients with PDAC, divided into groups of moderate (G2) and low degree of tumor differentiation (G3).

Results. PDAC was characterized by low levels of E-cadherin expression in both ducts and EMT – Me = 22.58 % [12.81; 36.23] and Me = 25.17 % [19.04; 35.37], respectively (p > 0.05). Only membrane expression of the marker was detected in the ducts and membrane-cytoplasmic one – in the EMT zone without significant differences in the groups. There was a significant decrease in the ductal β-catenin expression (p < 0.05) in G2 with membrane-cytoplasmic staining (Me = 15.58 % [10.42; 26.24]), in G3 – with membrane (Me = 4.42 % [2.35; 5.93]); in the EMT zone, only membrane-cytoplasmic expression was observed in both groups without significant difference (p > 0.05). Membrane expression of CK7 was positive in 100 % of PDAC, significantly lower at G2 (Me = 19.51 % [10.70; 27.24]; Me = 26.19 % [20.93; 30.05], p < 0.05), and CK18 (Me = 21.34 % [9.68; 29.96] – in G2, in G3 – Me = 22.50 % [8.24; 40.08], p > 0.05). Expression of α-SMA and Vim was seen in spindle-shaped stromal cells, around tubular and trabecular structures with membrane-cytoplasmic staining. There was no significant difference between α-SMA in G2 and G3, the level of vimentin was significantly lower in G3 (p < 0.05).

Conclusions. The features of PDAC E-cadherin, β-catenin, CK7 and CK18 marker expression indicate a greater EMT process at the periphery of the tumor and its severity increases with tumor progression. The optimal markers to determine the mesenchymal phenotype of PDAC cells are α-SMA and vimentin.

Author Biographies

M. A. Shyshkin, Zaporizhzhia State Medical and Pharmaceutical University, Ukraine

MD, PhD, DSc, Associate Professor, Professor of the Department of Pathological Anatomy and Forensic Medicine

V. O. Kabachenko, Zaporizhzhia State Medical and Pharmaceutical University, Ukraine

MD, PhD, DSc, Associate Professor, Professor of the Department of Pathological Anatomy and Forensic Medicine

References

Safa AR. Epithelial-mesenchymal transition: a hallmark in pancreatic cancer stem cell migration, metastasis formation, and drug resistance. J Cancer Metastasis Treat. 2020;6:36. doi: https://doi.org/10.20517/2394-4722.2020.55

Ribatti D, Tamma R, Annese T. Epithelial-Mesenchymal Transition in Cancer: A Historical Overview. Transl Oncol. 2020;13(6):100773. doi: https://doi.org/10.1016/j.tranon.2020.100773

Lee AYL, Dubois CL, Sarai K, Zarei S, Schaeffer DF, Sander M, et al. Cell of origin affects tumour development and phenotype in pancreatic ductal adenocarcinoma. Gut. 2019;68(3):487-98. doi: https://doi.org/10.1136/gutjnl-2017-314426

Romeo E, Caserta CA, Rumio C, Marcucci F. The Vicious Cross-Talk between Tumor Cells with an EMT Phenotype and Cells of the Immune System. Cells. 2019;8(5):460. doi: https://doi.org/10.3390/cells8050460

Liao TT, Yang MH. Hybrid Epithelial/Mesenchymal State in Cancer Metastasis: Clinical Significance and Regulatory Mechanisms. Cells. 2020;9(3):623. doi: https://doi.org/10.3390/cells9030623

Monkman JH, Thompson EW, Nagaraj SH. Targeting Epithelial Mesenchymal Plasticity in Pancreatic Cancer: A Compendium of Preclinical Discovery in a Heterogeneous Disease. Cancers (Basel). 2019;11(11):1745. doi: https://doi.org/10.3390/cancers11111745

Rodríguez Gil Y, Jiménez Sánchez P, Muñoz Velasco R, García García A, Sánchez-Arévalo Lobo VJ. Molecular Alterations in Pancreatic Cancer: Transfer to the Clinic. Int J Mol Sci. 2021;22(4):2077. doi: https://doi.org/10.3390/ijms22042077

Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019;20(2):69-84. doi: https://doi.org/10.1038/s41580-018-0080-4

Loh CY, Chai JY, Tang TF, Wong WF, Sethi G, Shanmugam MK, et al. The E-Cadherin and N-Cadherin Switch in Epithelial-to-Mesenchymal Transition: Signaling, Therapeutic Implications, and Challenges. Cells. 2019;8(10):1118. doi: https://doi.org/10.3390/cells8101118

Yu W, Yang L, Li T, Zhang Y. Cadherin Signaling in Cancer: Its Functions and Role as a Therapeutic Target. Front Oncol. 2019;9:989. doi: https://doi.org/10.3389/fonc.2019.00989

Sommariva M, Gagliano N. E-Cadherin in Pancreatic Ductal Adenocarcinoma: A Multifaceted Actor during EMT. Cells. 2020;9(4):1040. doi: https://doi.org/10.3390/cells9041040

Dmello C, Srivastava SS, Tiwari R, Chaudhari PR, Sawant S, Vaidya MM. Multifaceted role of keratins in epithelial cell differentiation and transformation. J Biosci. 2019;44(2):33

Cheng Y, Qin K, Huang N, Zhou Z, Xiong H, Zhao J, et al. Cytokeratin 18 regulates the transcription and alternative splicing of apoptotic related genes and pathways in HeLa cells. Oncol Rep. 2019;42(1):301-12. doi: https://doi.org/10.3892/or.2019.7166

Sousa B, Pereira J, Paredes J. The Crosstalk Between Cell Adhesion and Cancer Metabolism. Int J Mol Sci. 2019;20(8):1933. doi: https://doi.org/10.3390/ijms20081933

Palamaris K, Felekouras E, Sakellariou S. Epithelial to Mesenchymal Transition: Key Regulator of Pancreatic Ductal Adenocarcinoma Progression and Chemoresistance. Cancers (Basel). 2021;13(21):5532. doi: https://doi.org/10.3390/cancers13215532

Sánchez-Ramírez D, Medrano-Guzmán R, Candanedo-González F, De Anda-González J, García-Rios LE, Pérez-Koldenkova V, et al. High expression of both desmoplastic stroma and epithelial to mesenchymal transition markers associate with shorter survival in pancreatic ductal adenocarcinoma. Eur J Histochem. 2022;66(1):3360. doi: https://doi.org/10.4081/ejh.2022.3360

Published

2024-03-29

How to Cite

1.
Shyshkin MA, Kabachenko VO. Immunohistochemical characteristics of epithelial-mesenchymal transition in pancreatic ductal adenocarcinoma. Zaporozhye Medical Journal [Internet]. 2024Mar.29 [cited 2024Nov.27];26(2):127-33. Available from: http://zmj.zsmu.edu.ua/article/view/297243